Indeed, previous studies have demonstrated that FXR agonists inhibit gastrointestinal inflammation through direct actions on immune cells to preserve the intestinal barrier during inflammatory bowel disease (49). The gene discussed is NR1H4; the disease is inflammatory bowel disease.